Mohamed Maher | Material Science | Impactful Research Award
Dr. Mohamed Maher, University of Texas Southwestern Medical Center, United States.


Publication profile
Scopus
Education and Experience
Educationย 
- Ph.D. in Cancer Biologyย (Molecular Virology and Immunology) โ National Cancer Institute, Cairo University, Egypt (2011โ2017)
- M.Sc. in Pharmaceutical Sciencesย (Microbiology and Immunology) โ Assiut University, Egypt (2006โ2010)
- B.Sc. in Pharmaceutical Sciencesย โ Assiut University, Egypt (1998โ2003)
Experienceย 
- Senior Research Assistantย โ MD Anderson Cancer Center, Houston, TX (2022โPresent)
- Postdoctoral Fellowย โ MD Anderson Cancer Center, Houston, TX (2019โ2022)
- Lecturer of Cancer Biology, Virology, and Immunologyย โ South Egypt Cancer Institute, Assiut University, Egypt (2017โPresent)
- Assistant Lecturerย โ South Egypt Cancer Institute, Assiut University, Egypt (2015โ2017)
Suitability For The Award
Dr. Mohamed Maher stands as a distinguished cancer researcher whose transformative contributions to molecular diagnostics and cancer genomics make him an ideal candidate for the prestigious Impactful Research Award. His innovative work in cancer genotyping, particularly in liquid biopsies, solid tumors, and hematological malignancies, underscores his dedication to advancing diagnostic precision and improving patient outcomes. Dr. Maherโs expertise, blending his background as a Clinical Pharmacist, Cancer Biologist, and Molecular Diagnostic innovator, highlights his remarkable ability to translate cutting-edge research into real-world clinical applications, creating a lasting impact in cancer research and diagnostics.
Professional Developmentย
Publications Top Notes
-
“A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens”ย (Maher, M.H., et al., 2025,ย Cancer Cytopathology) โย
ย 2025 |ย
ย Open Access |ย
ย
-
“Dinutuximab synergistically enhances the cytotoxicity of natural killer cells to retinoblastoma through the perforin-granzyme B pathway”ย (Wang, H., et al., 2020,ย OncoTargets and Therapy) โย
ย 2020 |ย
ย 8 Citationsย